Thymosin Alpha-1 Guide

Thymosin alpha-1 (Ta1) is a peptide naturally produced from a precursor protein, prothymosin alpha, and first isolated from thymus tissue. The thymus is the organ where T cells, a key part of the immune system, mature. Thymus function declines with age, which is part of why thymic peptides have drawn interest in longevity medicine.

A synthetic version called thymalfasin is marketed outside the United States as Zadaxin and is approved in a number of countries, primarily for chronic hepatitis B.

Thymosin alpha-1 is considered an immune modulator rather than a simple immune booster. Research suggests it supports T-cell maturation and function, influences dendritic cells that coordinate immune responses, and affects signaling pathways involved in recognizing infections. The goal is better-balanced immune activity, which is why it has been studied both for infections and for conditions involving immune dysfunction.

FDA's 2024 review evaluated thymosin alpha-1 for a wide range of proposed uses, including hepatitis B and C, HIV, COVID-19, poor response to vaccination, melanoma, liver cancer, lung cancer, sepsis, infections after stem cell transplant, COPD, and chronic fatigue syndrome.

The strongest clinical record is in chronic hepatitis B, which led to its approval in other countries. Results in other areas, including sepsis and COVID-19, have been mixed, and FDA's advisory committee members cited a lack of convincing effectiveness data for the uses reviewed.

In clinical studies, thymosin alpha-1 has generally been well tolerated, with injection-site reactions among the most common effects. FDA's safety summary notes that compounded thymosin alpha-1 may pose a significant risk of immunogenicity, meaning the body may react to the product itself, and that available safety information is inadequate to fully understand the risks of compounded versions.

Because it acts on the immune system, people with autoimmune conditions, organ transplants, or who take immunosuppressive medications require careful evaluation. It is not used during pregnancy without specialist guidance.

Thymosin alpha-1 is not FDA-approved in the United States. It is not on FDA's list of bulk substances approved for compounding, and at a December 4, 2024 meeting, FDA's Pharmacy Compounding Advisory Committee voted against adding it to that list. Federal health officials have signaled that several peptides may be reconsidered, and the rules have changed repeatedly since 2023, so current status should always be confirmed with your physician.